NCT02254538View on ClinicalTrials.gov

A Safety, Tolerability and Preliminary Pharmacokinetics of BILR 355 BS Single-rising Dose Study in Healthy Male Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

May 31, 2002

Primary Completion Date

February 28, 2003

Conditions
Healthy
Interventions
DRUG

BILR 355 BS

DRUG

PEG 400

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT02254538 - A Safety, Tolerability and Preliminary Pharmacokinetics of BILR 355 BS Single-rising Dose Study in Healthy Male Volunteers | Biotech Hunter | Biotech Hunter